The role of bile acid-activated receptor TGR5 in inflammation and liver diseases.
Takeda G-protein-coupled receptor 5 (TGR5), a bile acid receptor, has been recognized as an important signal molecule with roles extending far beyond bile acid homeostasis.
APA
Xiang H, Xiang H, et al. (2026). The role of bile acid-activated receptor TGR5 in inflammation and liver diseases.. Frontiers in physiology, 17, 1747341. https://doi.org/10.3389/fphys.2026.1747341
MLA
Xiang H, et al.. "The role of bile acid-activated receptor TGR5 in inflammation and liver diseases.." Frontiers in physiology, vol. 17, 2026, pp. 1747341.
PMID
41783801
Abstract
Takeda G-protein-coupled receptor 5 (TGR5), a bile acid receptor, has been recognized as an important signal molecule with roles extending far beyond bile acid homeostasis. Its activation has been shown to ameliorate metabolic disorders and suppress inflammatory responses through diverse mechanisms. Expressed widely in both parenchymal and non-parenchymal cells of the liver, TGR5 plays a central role in hepatic physiology and disease. This review consolidates current evidence on the involvement of TGR5 in various liver pathologies, including metabolic dysfunction-associated steatohepatitis, cholestatic diseases, liver fibrosis, and hepatocellular carcinoma. Additionally, we summarize the regulatory functions of TGR5 in immune cells and inflammatory signaling pathways. We emphasize TGR5 as a promising therapeutic target for a range of chronic liver diseases, given its pivotal role in modulating inflammation and metabolism. Future research should focus on developing tissue-specific TGR5 agonists to enhance therapeutic efficacy and reduce systemic side effects, as well as elucidating its context-dependent dual roles in hepatocarcinogenesis to ensure safe clinical application.
같은 제1저자의 인용 많은 논문 (5)
- The landscape of tissue-resident microbiota across normal, polyp, and colorectal cancer tissues.
- Medicarpin reduces cisplatin resistance and causes apoptosis by inhibiting the AKT/Bcl2 pathway in breast cancer.
- Predominant mutated non-canonical tumor-specific antigens identified by proteogenomics demonstrate immunogenicity and tumor suppression in CRC.
- Multi-colorized tint map for distinguishing triple-negative breast cancers from cysts and fibroadenomas based on the tumor margin.
- A microfluidic tumor-on-chip platform deciphers hypoxia-driven FOXO3a/PD-L1 signaling in gastric cancer immunotherapy resistance.